Synergistic Liposome Compositions for Targeted Therapeutic Delivery

Publication ID: 24-11857509_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Liposome Compositions for Targeted Therapeutic Delivery,” Published Technical Disclosure No. 24-11857509_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857509_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,509.

Summary of the Inventive Concept

The inventive concept integrates pH-sensitive liposomes with AI, IoT, blockchain, and other distinct technologies to create a more powerful system for targeted delivery of therapeutic molecules to diseased tissue.

Background and Problem Solved

The original patent disclosed pH-sensitive liposomes for delivering molecules to cells, but it had limitations in terms of targeted delivery and real-time monitoring. The new inventive concept addresses these limitations by combining the liposomes with AI-powered diagnostic modules, IoT-enabled biosensors, and blockchain-based tracking systems to achieve more efficient and personalized treatment outcomes.

Detailed Description of the Inventive Concept

The synergistic liposome compositions comprise pH-sensitive liposomes integrated with AI-powered diagnostic modules for identifying optimal treatment sites, IoT-enabled biosensors for real-time pH level detection, and blockchain-based tracking systems for monitoring delivery efficacy. The AI module analyzes patient data and identifies the most effective treatment sites, while the IoT biosensors transmit pH level data to a cloud-based analytics platform for real-time treatment optimization. The blockchain-based tracking system ensures the integrity and security of the delivery process. The compositions can be adapted for personalized cancer treatment, synergistic delivery of multiple therapeutic agents, and real-time monitoring of liposome-mediated delivery.

Novelty and Inventive Step

The new claims introduce the integration of AI, IoT, and blockchain technologies with pH-sensitive liposomes, which is a non-obvious and novel combination that significantly enhances the targeted delivery of therapeutic molecules. The inventive concept's synergistic approach provides a more efficient, personalized, and secure treatment outcome compared to the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of different AI algorithms, IoT sensor types, or blockchain protocols. Variations of the composition may include the integration of additional technologies, such as microRNA-based targeting mechanisms or nanoparticle-based delivery systems.

Potential Commercial Applications and Market

The synergistic liposome compositions have significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of targeted cancer therapy, personalized medicine, and real-time treatment monitoring. The market for these compositions is expected to grow rapidly as the demand for more efficient and effective treatment outcomes increases.

CPC Classifications

SectionClassGroup
A A61 A61K9/1271
A A61 A61K9/127
A A61 A61K31/20
A A61 A61K31/337
A A61 A61K31/704
A A61 A61K31/711
A A61 A61K31/713
A A61 A61K31/7105
A A61 A61K47/6911
A A61 A61P35/00

Field of Art

Pharmaceutical drug delivery systems, specifically targeted liposomal drug delivery technologies with a focus on pH-sensitive targeting mechanisms for therapeutic interventions

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with expertise in pharmaceutical formulation, nanotechnology, and targeted drug delivery systems, holding advanced degrees in biomedical engineering, chemistry, or pharmaceutical sciences, with working knowledge of emerging technologies in medical diagnostics and delivery platforms

Obviousness Rationale

A person having ordinary skill in the art would recognize that integrating digital technologies with existing pH-sensitive liposomal delivery systems represents a predictable extension of known targeted drug delivery approaches. The combination of AI, IoT, and blockchain with established liposomal targeting mechanisms follows a logical progression of enhancing therapeutic precision and monitoring capabilities. The fundamental principles of pH-sensitive targeting remain consistent, with technological additions providing incremental improvements in tracking and optimization.

Obvious Combinations & Variations

Source Patent Element
pH-sensitive liposomes with pHLIP for targeted cellular delivery
PTD Variation
Integration of AI-powered diagnostic modules for identifying optimal treatment sites
Obviousness Reasoning
Predictable application of machine learning to existing targeted delivery technologies, representing a known technique for improving treatment precision
Source Patent Element
Cellular membrane fusion and endosomal delivery mechanisms
PTD Variation
IoT-enabled biosensors for real-time pH level detection and treatment monitoring
Obviousness Reasoning
Logical extension of existing delivery monitoring techniques using emerging sensor technologies, providing enhanced data collection about delivery mechanisms
Source Patent Element
Liposomal cargo delivery to specific cellular environments
PTD Variation
Blockchain-based tracking system for ensuring delivery integrity and documenting treatment processes
Obviousness Reasoning
Predictable application of distributed ledger technologies to medical delivery systems, representing a known approach for improving documentation and verification
Source Patent Element
pH-sensitive targeting of specific cellular microenvironments
PTD Variation
Nanoparticle-based delivery system combined with microRNA-based targeting mechanisms
Obviousness Reasoning
Finite set of known techniques for enhancing targeted delivery, representing a design choice within the existing technological landscape
Source Patent Element
Liposomal compositions for molecular delivery
PTD Variation
Cloud-based analytics platform for real-time treatment optimization
Obviousness Reasoning
Predictable integration of data analytics with existing delivery technologies, representing a standard approach to improving treatment protocols
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857509 and the disclosed variations, a person having ordinary skill in the art would find the claimed innovations obvious and lacking inventive step. The combination of pH-sensitive liposomal delivery mechanisms with digital technologies represents a predictable evolution of existing targeted drug delivery approaches, rendering subsequent claims of novelty unpersuasive under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,509
TitleLiposome compositions and methods of use thereof
Assignee(s)Yale University, University of Rhode Island Board of Trustees